Target intelligence / Profile preview

Leucine-rich repeat-containing protein 31 (LRRC31)

Target
LRRC31
Molecular classification
Other (LRRC family member, leucine-rich repeat-containing protein; not a classic receptor, enzyme, transporter, GPCR, ion channel, or transcription factor)
01

Overview

Leucine-rich repeat-containing protein 31 (LRRC31) is a nuclear protein characterized by multiple leucine-rich repeat motifs, forming a horseshoe-like structure that mediates protein-protein interactions essential for DNA damage response. LRRC31 specifically inhibits non-homologous end joining (NHEJ) DNA double-strand break repair through direct interaction with ATR and Ku70/Ku80 complex, impacting the recruitment and activation of DNA-PKcs and interfering with the MSH2-ATR signaling module. In epithelial tissues, LRRC31 is induced by IL-13 and enhances epithelial barrier function, in part by downregulating multiple kallikrein-related serine proteases (KLKs). LRRC31 is implicated in human diseases including cancer (as a tumor suppressor and radiosensitizing factor in breast cancer brain metastasis) and inflammatory disorders like eosinophilic esophagitis (where it may serve as an early biomarker of response to therapy)[1][3].

Other names
LRRC31UNQ9367/PRO34156FLJ23259HEL-S-293Epididymis secretory protein Li 293Epididymis secretory sperm binding protein
02

Mechanism of action

As a radiosensitizing gene, modulation of LRRC31 inhibits DNA repair protein recruitment and disrupts downstream signaling pathways (e.g., ATR-MSH2 complex) leading to increased radiosensitivity of cancer cells[1].

03

Biological functions

Regulation of DNA double-strand break repair (inhibiting non-homologous end joining – NHEJ)Modulation of protein-protein interactions (with ATR, Ku70/Ku80, MSH2)Regulation of epithelial barrier function (via modulation of serine proteases and response to IL-13 in epithelial cells)
04

Disease associations

Cancer (notably breast cancer brain metastasis, through modulation of DNA repair and radiosensitivity)Inflammatory disease (notably eosinophilic esophagitis, through epithelial barrier regulation)
05

Safety considerations

No specific safety liabilities or therapeutic challenges have been reported for targeting LRRC31; however, its broad role in normal DNA repair and epithelial function suggests that off-target effects may be possible[1][3].
06

Biomarkers

LRRC31 mRNA expression is proposed as a potential biomarker of response in certain esophageal inflammatory conditions (e.g., eosinophilic esophagitis)[3].

Beyond the preview

Go deeper on Leucine-rich repeat-containing protein 31 (LRRC31).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leucine-rich repeat-containing protein 31 (LRRC31).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call